Read + Share
Sharma M, Srivastava A. In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC
therapy did not affect net clinical benefit at 2 y. Ann Intern Med 2026 Feb 3. doi: 10.7326/ANNALS-25-05308.
PMID: 41628452
|
 |
|
Sharma M, Srivastava A. In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC
therapy did not affect net clinical benefit at 2 y. Ann Intern Med 2026 Feb 3. doi: 10.7326/ANNALS-25-05308.
PMID: 41628452
|
|
|
|